CUBE vs SPRY · P/E 25, rev $1.07B vs rev $89.1M
CubeSmart (CUBE) versus ARS Pharmaceuticals, Inc (SPRY) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported SPRY revenue for 2024-12-31 was $89.1M. Net income was $8.0M. Revenue was up 297063.3% from 2023-12-31 to 2024-12-31. SPRY currently screens at market cap $983.1M.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. SPRY currently screens at market cap $983.1M.
Not investment advice. Open the CUBE and SPRY stock pages for the full models.
Not investment advice.